Sign in

Painful bone metastases: radiation, bone agents and cord compression

Cancer and cancer-related pain · C5 · Reviewed by a board-certified pain physician on October 31, 2026

Bottom line

External beam radiation is the core treatment for painful bone metastases, and a single 8 Gy fraction relieves pain as well as longer courses. Cord compression needs dexamethasone and urgent surgical and radiation review; bone agents are adjuncts, not analgesics.

Key points

  1. Radiate painful bone metastases. ASTRO 2024 recommends radiation for pain from bone and spine metastases, with or without cord or cauda equina compression 1.
  2. Single fraction equals multiple fractions for pain. Acceptable conventional regimens are 8 Gy in 1, 20 Gy in 5, 24 Gy in 6 or 30 Gy in 10 fractions, and pain relief is equivalent between single and multiple fractions 12.
  3. Choose by the whole person. The regimen should reflect prognosis, prior radiation, normal-tissue risk, quality of life, cost and patient goals, with shared decision-making 1.
  4. SBRT is for selected patients. It is conditionally recommended over conventional radiation only for good performance status without need for surgery or neurologic signs 1.
  5. Cord compression: steroids, then surgery plus radiation. Dexamethasone is recommended for spine metastases compressing the cord or cauda equina, and surgery with postoperative radiation is conditionally preferred over radiation alone 1.
  6. Bone-modifying agents prevent events but barely treat pain. ASCO-CCO recommends them for breast cancer with bone metastases; their analgesic effect is modest, so they should not be used alone for bone pain; analgesics, radiotherapy and supportive care continue 3.

Watch for

Metastatic compression of the spinal cord or cauda equina is not managed with analgesics and observation: give dexamethasone and involve surgery and radiation oncology, since surgery plus radiation is conditionally preferred 1.

High-yield for the exam

  • Retreatment of recurrent pain at peripheral or spine sites is safe and effective within published dose constraints 2.
  • Surgery, radionuclides, bisphosphonates and vertebral augmentation do not remove the need for external beam radiation 2.
  • For surgery-ineligible cord compression, ASTRO lists 8 Gy/1, 16 Gy/2, 20 Gy/5 or 30 Gy/10 1.
  • Patients with nonspine bone metastases needing surgery are recommended postoperative radiation 1.
  • Evidence is insufficient to prefer one bone-modifying agent over another 3.
  • Denosumab is contraindicated in hypocalcemia, which must be corrected first; supplement calcium and vitamin D 4.
  • Perform an oral examination before denosumab and avoid invasive dental work because of osteonecrosis of the jaw 4.

Numbers to know

Item Value
Single-fraction dose 8 Gy (800 cGy) 1
Multifraction options 20/5, 24/6, 30/10 Gy/fractions 1
Denosumab 120 mg SC every 4 weeks 3
Zoledronic acid 4 mg IV every 12 weeks or every 3–4 weeks 3
Pamidronate 90 mg IV every 3–4 weeks 3
Spine reirradiation options 8/1, 20/5, 24/6, 20/8 Gy/fractions 1

Common traps

  • Assuming longer fractionated courses relieve pain better than a single 8 Gy fraction 2.
  • Assuming single fractions are unsafe for spine lesions; high-quality data show acceptable late toxicity 2.
  • Relying on a bisphosphonate to treat acute cord compression 13.
  • Offering SBRT to a patient with poor performance status 1.

Practise this topic

6 more questions on this topic in the full question bank, with explanations and sources.

Sources

  1. Alcorn S, et al. External beam radiation therapy for palliation of symptomatic bone metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol, 2024. pubmed.ncbi.nlm.nih.gov/38788923/
  2. Lutz S, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol, 2017. pubmed.ncbi.nlm.nih.gov/27663933/
  3. Van Poznak C, et al. Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol, 2017. pubmed.ncbi.nlm.nih.gov/29035643/
  4. US Food and Drug Administration. XGEVA (denosumab) injection prescribing information. DailyMed, 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=628f0998-12

Related topics

Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.